STALICLA 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mavoglurant (STP7) / STALICLA
Parkinson disease-1: AFQ056 in Phase III development for the treatment of Parkinson's disease levodopa-induced dyskinesia.

Ongoing
3
0
RestOfWorld
mavoglurant (AFQ056)
Novartis
Parkinson's Disease
 
 
NCT06136195: Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

Recruiting
2
63
US
Mavoglurant, STP7
Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Consumption, Heavy Drinker, Alcohol Use Disorder (AUD)
05/26
05/26
2010-019353-18: Two-period, single-dose pharmacokinetic study in male adolescent patients with Fragile X Syndrome (FXS).

 
1
NA
AFQ056, AFQ056,
Novartis Pharma Services AG, Novartis Pharma Services AG
Fragile X Syndrome
 
 
NCT03327792: Mavoglurant in Alcohol Drinking

Completed
1
34
US
Mavoglurant, Placebo
Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Drinking
07/23
07/23
STA-P7-C001, NCT06273540: Phase1, STP7 Cocaine Drug-Drug Interaction Study

Completed
1
21
US
STP7 (mavoglurant) or Placebo, Cocaine, Saline infusion
Stalicla SA, National Institute on Drug Abuse (NIDA)
Cocaine Use Disorder
10/24
10/24
NCT05203965: Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

Recruiting
1
80
US
Mavoglurant (AFQ056), Placebo
Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Familial Alcoholism Vulnerability
07/26
07/26
Sulforadex (sulforafan alfadex) / Evgen Pharma, STALICLA
No trials found
ibudilast/bumetanide (STP1) / STALICLA
No trials found
STP2 / STALICLA
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mavoglurant (STP7) / STALICLA
Parkinson disease-1: AFQ056 in Phase III development for the treatment of Parkinson's disease levodopa-induced dyskinesia.

Ongoing
3
0
RestOfWorld
mavoglurant (AFQ056)
Novartis
Parkinson's Disease
 
 
NCT06136195: Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

Recruiting
2
63
US
Mavoglurant, STP7
Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Consumption, Heavy Drinker, Alcohol Use Disorder (AUD)
05/26
05/26
2010-019353-18: Two-period, single-dose pharmacokinetic study in male adolescent patients with Fragile X Syndrome (FXS).

 
1
NA
AFQ056, AFQ056,
Novartis Pharma Services AG, Novartis Pharma Services AG
Fragile X Syndrome
 
 
NCT03327792: Mavoglurant in Alcohol Drinking

Completed
1
34
US
Mavoglurant, Placebo
Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Drinking
07/23
07/23
STA-P7-C001, NCT06273540: Phase1, STP7 Cocaine Drug-Drug Interaction Study

Completed
1
21
US
STP7 (mavoglurant) or Placebo, Cocaine, Saline infusion
Stalicla SA, National Institute on Drug Abuse (NIDA)
Cocaine Use Disorder
10/24
10/24
NCT05203965: Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

Recruiting
1
80
US
Mavoglurant (AFQ056), Placebo
Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Familial Alcoholism Vulnerability
07/26
07/26
Sulforadex (sulforafan alfadex) / Evgen Pharma, STALICLA
No trials found
ibudilast/bumetanide (STP1) / STALICLA
No trials found
STP2 / STALICLA
No trials found

Download Options